

RESEARCH ARTICLE

# Validation of surrogate markers for metabolic syndrome and cardiometabolic risk factor clustering in children and adolescents: A nationwide population-based study

Ji-Young Seo<sup>1</sup>, Jae Hyun Kim<sup>2\*</sup>

**1** Department of Pediatrics, Nowon Eulji Medical Center, Eulji University, Seoul, Korea, **2** Department of Pediatrics, Seoul National University Bundang Hospital, Seongnam, Korea

\* [pedendo@snuh.org](mailto:pedendo@snuh.org)



**OPEN ACCESS**

**Citation:** Seo J-Y, Kim JH (2017) Validation of surrogate markers for metabolic syndrome and cardiometabolic risk factor clustering in children and adolescents: A nationwide population-based study. PLoS ONE 12(10): e0186050. <https://doi.org/10.1371/journal.pone.0186050>

**Editor:** Ying-Mei Feng, Beijing Key Laboratory of Diabetes Prevention and Research, CHINA

**Received:** April 4, 2017

**Accepted:** September 25, 2017

**Published:** October 19, 2017

**Copyright:** © 2017 Seo, Kim. This is an open access article distributed under the terms of the [Creative Commons Attribution License](https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

**Data Availability Statement:** All files are available from the KNHANES webpage (URL: <https://knhanes.cdc.go.kr/eng/knhanes/index.do>) At the webpage above mentioned, when you clicked 'Survey Data' -> 'Data Downloads', you can enter the 'login' page. At that webpage, there was a guide for data data download. Requests for data or questions can be directed to [sun4070@korea.kr](mailto:sun4070@korea.kr) (+82-43-719-7467).

**Funding:** This study was funded by the EMBRI Grants 2012EMBRISN0002 from the Eulji

## Abstract

Prevalence of metabolic syndrome (MetS) in children is increasing and identifying the risk factors for MetS during childhood is an important first step to prevent chronic diseases later in life. The aim of the present study was to evaluate the prevalence of MetS and cardiometabolic risk factor (CMRF) clustering among Korean children and adolescents and to validate the associated anthropometric and laboratory surrogate markers. We used data from the 2011–2014 Korean National Health and Nutrition Examination Survey. In total, data for 2,935 subjects (1539 boys, 52.6%) aged 10–19 years were assessed. MetS was defined by central obesity plus any two or more of CMRFs such as abdominal obesity, hypertension, hyperglycemia, hypertriglyceridemia, and decreased high density lipoprotein cholesterol (HDL-C) using the International Diabetes Federation criteria for children and adolescents. The presence of two or more CMRFs was classified as CMRF clustering. The prevalence of MetS and CMRF clustering in this group was found to be 1.8% and 8.9%, respectively. The receiver operating characteristic analysis of MetS and CMRF clustering, and the area under the curve (95% confidence interval) of surrogate markers revealed that the waist circumference to height ratio [0.960 (95% CI 0.959–0.960), cut-off 0.491] showed the highest predictability for MetS whereas triglyceride to HDL-C ratio [0.891 (95% CI 0.891–0.892), cut-off 2.63] showed the highest predictability for CMRF clustering. Long-term follow-up is needed for further validation.

## Introduction

The metabolic syndrome (MetS) is generally defined as a cluster of metabolically related cardiovascular risk factors. MetS is becoming a major public health issue globally, because individuals with MetS have higher risk of developing type 2 diabetes and cardiovascular diseases (CVD) than those without it [1]. Prevalence of MetS in children is less than that of in adults; however, as prevalence of childhood obesity increases so does MetS [2, 3]. Identifying the

University. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

**Competing interests:** The authors have declared that no competing interests exist.

markers that can predict the emergence of MetS during childhood would be an important first step to prevent chronic diseases later in life. Cardiometabolic risk factor (CMRF) clustering indicated aggregation of several cardiometabolic risk factors, such as components of MetS. CMRF clustering have a tendency to tracking from childhood to adulthood, hence timely intervention in high-risk children may provide an early opportunity to decrease the progression to overt cardiovascular disease [4]. Recently, shifting the focus to CMRF is emphasized over the need to define a pediatric MetS [5]. However, data are not available regarding whether and how to best assess the individual risk for the presence of MetS and CMRF clustering in clinical pediatric practice [6, 7]. Several studies on the MetS and CVD have been conducted based on Korea National Health and Nutrition Examination Survey (KNHANES), which were mainly conducted for adults; however, recently, studies on the prevalence and degree of risk of MetS have also been performed in children [8–10]. Furthermore, most of the studies compared the prevalence of MetS based on the well-known predictors. In addition, detailed analysis on the most predictive factor of MetS and CMRF and the cut-off values are lacking.

The aim of this study was to evaluate the prevalence of MetS and CMRF clustering among Korean children aged 10–19 years, in addition to evaluating the validity of well-known and emerging anthropometric and laboratory markers, such as body mass index (BMI), waist circumference (WC) to height ratio (WHtR), triglyceride to high density lipoprotein cholesterol (TG/HDL-C) ratio, glycated hemoglobin (HbA1c) and elevated alanine transaminase (ALT).

## Materials and methods

### Study population and database

We used data from the Korea National Health and Nutrition Examination Surveys (KNHANES) (2011–2014). KNHANES represent a series of population-based, cross-sectional surveys that select a representative group by using a stratified, multi-stage sampling design according to geographic area, age, and gender. Detailed descriptions of the study design and data collection have been published [11]. In brief, 192 primary sampling units per year were extracted from the whole country during 2011–2014. Twenty households in each primary sampling unit were selected using systematic sampling. In the selected household, those aged 1 year or more were potential candidates for the survey, which consisted of a health interview, health examination and nutrition survey. The sampling weights were assigned for each participant and household to represent the whole Korean population. The response rate of the KNHANES was 80.8% in 2011–2012 and 78.3% in 2013–2014. Of the 32,144 participants, 3,813 participants aged 10–19 were selected. For one or more of the following reasons, a total of 861 subjects were excluded: no record of fasting time or fasting less than 8 hours ( $n = 415$ ); no anthropometric data ( $n = 304$ ); incomplete laboratory data ( $n = 845$ ); no blood pressure measurement ( $n = 309$ ). Thus, we had a final sample of 2,952 subjects (1,545 boys and 1,407 girls) for our analyses. The KNHANES was approved by Institutional Review Board of the Korea Centers for Disease Control & Prevention (KCDC) and the KCDC Bioethics Committee (approval number: 2011-02CON-06-C, 2012-01EXP-01-2C, 2013-07CON-03-4C, and 2013-12EXP-03-5C). Informed consent was obtained from all participants including children and adolescents and their legal guardian(s) or parent(s) before data collection for KNHANES. The present study protocol was approved from examination by the Clinical Examination Committee of Seoul Eulji Hospital of Eulji University (Institutional Review Board no. EMCIRB 17–27) and supported by EMBRI Grants 2012EMBRISN0002 from the Eulji University.

## Anthropometric and laboratory measurements

Height was measured using a stadiometer (Seca 225, Seca, Hamburg, Germany) to the nearest 0.1 cm. Weight was measured using an electronic balance (GL-6000-20, G-tech, Seoul, Korea) to the nearest 0.1 kg. BMI was calculated by dividing weight (kg) by height (m) squared. Height, weight, and BMI were converted to z-score for age and sex using the Korean reference [12]. Overweight and obesity was defined as having a BMI of 85–94<sup>th</sup> percentile and  $\geq 95^{\text{th}}$  percentile for corresponding age and sex, respectively. WC was measured at the midpoint between the lower borders of the rib cage and the iliac crest at the end of normal expiration. WHtR was calculated WC (cm)/height (cm). Plasma glucose, total cholesterol, HDL-C, TG, aspartate aminotransferase (AST) and ALT were measured using a Hitachi Automatic Analyzer 7600 (Hitachi, Tokyo, Japan). Non-HDL-C was calculated as follows: total cholesterol value—HDL-C value. TG/HDL-C ratio was calculated by TG over HDL-C. HbA1c was measured using high performance liquid chromatography (HLC-723G7; Tosoh, Tokyo, Japan), which is the certified method by the National Glycohemoglobin Standardization Program.

## Definition of metabolic syndrome and cardiometabolic risk factors

Metabolic syndrome was defined by the International Diabetes Federation (IDF) criteria for children and adolescents [13]. The presence of two or more CMRFs such as abdominal obesity, hypertension, hyperglycemia, hypertriglyceridemia, and decreased HDL-C was classified as CMRF clustering.

Abdominal obesity was defined by WC  $\geq 90^{\text{th}}$  percentile using Korean waist reference data for those younger than 16 years of age. For boys and girls older than 16 years of age, a WC of more than 90 cm and more than 85 cm was used respectively to define central obesity based on Korean-specific WC cut-off points [14]. Hypertension was defined by systolic blood pressure (SBP)  $\geq 130$  mm Hg or diastolic BP (DBP)  $\geq 85$  mm Hg. Hyperglycemia was defined by fasting glucose  $\geq 100$  mg/dL, and hypertriglyceridemia was defined by fasting TG level  $\geq 150$  mg/dL. Decreased HDL-C was defined as HDL-C level of  $< 40$  mg/dL for boys aged 10–19 years and girls younger than 16 years of age; for girls 16 years of age and above it was  $< 50$  mg/dL. Elevated ALT was defined as  $\geq 35$  IU/L for boys and  $\geq 24$  IU/L for girls [15].

## Statistical analysis

Stata 14.2 (StataCorp LP, College Station, Texas, USA) was used for the statistical analysis. According to the design of KNHANES, appropriate weights for each sample were applied for the analysis. Data were stated as weighted mean  $\pm$  standard error (SE) for the continuous variables or the number of cases with weighted percent. Total cholesterol, TG, HDL-C, non-HDL-C, and TG/HDL-C ratio were log-transformed and stated as geometric mean  $\pm$  SE. Student t-test for the continuous variables and chi-square test for the categorical variables were used. Logistic regression analysis was performed to evaluate the association between the surrogate markers, MetS and CMRF clustering in addition to calculating the odds ratio (OR) with 95% confidence interval (CI). To validate surrogate markers as a predictor of multiple CMRFs and MetS, the area under the curve (AUC) was calculated from the receiver operating characteristic (ROC) curve [16]. The best cut-off point was determined using Youden index as [maximum (J = sensitivity + specificity—1)];  $P < 0.05$  was considered significant.

## Results

### Anthropometric, clinical, and biochemical characteristics of participants by gender

The general characteristics of the study subjects are shown in Table 1. The mean age of the subjects was  $14.8 \pm 0.1$  years, and the mean BMI was  $20.9 \pm 0.1$  kg/m<sup>2</sup>. Overall, 13.1% of the subjects (14.3% of boys and 11.9% of girls) were overweight and 12.8% of the subjects (15.0% of boys and 10.3% of girls) were obese. The prevalence of being overweight and obese was higher

**Table 1. Anthropometric, clinical, and biochemical characteristics in study participants.**

	Total (n = 2935, 100%)	Boys (n = 1539, 52.6%)	Girls (n = 1396, 47.4%)	P value
Estimated population	5,191,866	2,728,574	2,463,292	-
Age (years)	14.8 ± 0.1	14.8 ± 0.1	14.9 ± 0.1	0.265
Height (cm)	162.4 ± 0.2	166.3 ± 0.4	158.1 ± 0.2	<0.001
Height z-score	0.35 ± 0.03	0.41 ± 0.03	0.28 ± 0.04	0.003
Weight (kg)	55.9 ± 0.3	59.6 ± 0.5	51.9 ± 0.4	<0.001
Weight z-score	0.18 ± 0.03	0.20 ± 0.04	0.16 ± 0.04	0.343
Body mass index (kg/m <sup>2</sup> )	20.9 ± 0.1	21.2 ± 0.1	20.6 ± 0.1	<0.001
BMI z-score	0.02 ± 0.03	0.01 ± 0.04	0.04 ± 0.04	0.571
BMI classification				
Normal (%)	2210 (74.1%)	1114 (70.7%)	1096 (77.8%)	0.001
Overweight (%)	380 (13.1%)	211 (14.3%)	169 (11.9%)	
Obese (%)	345 (12.8%)	214 (15.0%)	131 (10.3%)	
Waist circumference (cm)	70.2 ± 0.2	72.2 ± 0.3	67.9 ± 0.3	<0.001
Waist circumference to height ratio	0.432 ± 0.001	0.434 ± 0.002	0.429 ± 0.002	0.041
Systolic blood pressure (mm Hg)	107.6 ± 0.2	110.0 ± 0.3	104.9 ± 0.3	<0.001
Diastolic blood pressure (mm Hg)	66.5 ± 0.2	66.9 ± 0.3	66.0 ± 0.3	0.019
Total cholesterol (mg/dL)	156.3 ± 0.7	151.5 ± 0.9	161.8 ± 0.9	<0.001
Triglyceride (mg/dL)	73.8 ± 0.9	73.1 ± 1.2	74.6 ± 1.3	0.358
HDL-C (mg/dL)	49.4 ± 0.3	47.6 ± 0.3	51.4 ± 0.4	<0.001
Non-HDL-C (mg/dL)	105.1 ± 0.7	102.4 ± 0.9	108.3 ± 0.9	<0.001
Triglyceride/HDL-C ratio	1.48 ± 0.03	1.51 ± 0.03	1.45 ± 0.03	0.186
Fasting glucose (mmol/L)	4.99 ± 0.01	5.01 ± 0.01	4.96 ± 0.02	0.042
HbA1c (%)	5.45 ± 0.01	5.46 ± 0.01	5.45 ± 0.01	0.441
Serum AST (IU/L)	18.6 ± 0.2	20.3 ± 0.2	16.8 ± 0.2	<0.001
Serum ALT (IU/L)	15.1 ± 0.3	18.1 ± 0.5	11.7 ± 0.2	<0.001
Metabolic syndrome (%)	31 (1.8%)	18 (1.9%)	13 (1.7%)	0.765
CMRF clustering (%)	188 (8.9%)	109 (9.4%)	79 (8.2%)	0.407
Abdominal obesity (%)	243 (9.1%)	119 (8.2%)	124 (10.2%)	0.109
Hypertension (%)	92 (3.6%)	70 (5.6%)	22 (1.5%)	<0.001
Hyperglycemia (%)	207 (7.0%)	128 (8.2%)	79 (5.6%)	0.015
Hypertriglyceridemia (%)	229 (8.6%)	133 (9.3%)	96 (7.9%)	0.254
Low HDL-C (%)	389 (18.2%)	207 (17.7%)	182 (18.7%)	0.614
Elevated ALT (%)	146 (5.1%)	102 (7.0%)	44 (3.1%)	<0.001

BMI: body mass index; HDL-C: high density lipoprotein cholesterol; aspartate transaminase; HbA1c: glycated hemoglobin; ALT: alanine transaminase; CMRF: cardio metabolic risk factor.

Data were expressed as weight mean ± standard error or number of cases (weighted percent).

Total cholesterol, triglyceride, HDL-C, non-HDL cholesterol and TG/HDL-C ratio were log-transformed and expressed as geometric mean ± standard error.

<https://doi.org/10.1371/journal.pone.0186050.t001>

in boys. Furthermore, boys had elevated WC, WHtR, BP, fasting glucose, HbA1c, AST and ALT, whereas girls had elevated TC, HDL-C, and non-HDL-C levels.

The prevalence of MetS and CMRF clustering were found as 1.8% and 8.9% respectively. There were no significant differences between boys and girls. Boys also had higher metabolic co-morbidities such as hypertension (5.6% in boys and 1.5% in girls), hyperglycemia (8.2% in boys and 5.6% in girls), elevated ALT (7.0% in boys and 3.1% in girls). However, there was no significant difference between boys and girls for abdominal obesity, hypertriglyceridemia, and low HDL-C (Table 1).

### Association between parameters and metabolic syndrome or CMRF clustering by gender

On multiple logistic regression analysis adjusted for age and gender, predictors for MetS were BMI z-score [OR 11.4 (95% CI 7.3–17.8),  $P < 0.01$ ], HbA1c [OR 1.8 (95% CI 1.3–2.6),  $P < 0.01$ ], TG/HDL-C ratio [OR 2.3 (95% CI 1.8–3.0),  $P < 0.01$ ] and WHtR [OR 1.4 (95% CI 1.3–1.5),  $P < 0.01$ ] were also significantly associated with MetS. When we analyzed this factors by age group (10–15 years vs 16–19 years), similar analytic tendency was showed. There was no statistically significant gender difference in the prevalence of MetS with the increase of HbA1c, and the OR of BMI z-score was higher in boys as compared with girls (15.4 vs 8.9) (Table 2).

When CMRF clustering and surrogate markers were analyzed by the same method, HbA1c [OR 2.1 (95% CI 1.1–4.0),  $P < 0.01$ ], BMI z-score [OR 4.1 (95% CI 3.2–5.2),  $P < 0.01$ ], TG/HDL-C ratio [OR 3.9 (95% CI 3.3–4.6),  $P < 0.01$ ] and WHtR [OR 1.3 (95% CI 1.3–1.4),  $P < 0.01$ ] showed a high correlation with CMRF clustering overall, similarly to those of MetS (Table 2).

### Predictors for MetS and CMRF clustering

After ROC analysis of MetS and CMRF clustering, AUC of surrogate markers revealed that BMI z-score [0.959 (95% CI 0.957–0.962)] and WHtR [0.960 (95% CI 0.959–0.960)] showed

**Table 2. Age- and sex-adjusted odds ratios (95% confidence intervals) of surrogate markers predicting metabolic syndrome and cardiometabolic risk factor (CMRF) clustering.**

Category	Surrogate markers	Total	10–15 years	16–19 years	Boys	Girls
Metabolic syndrome	HbA1c (%)	1.8 (1.3–2.6)**	1.8 (1.3–2.7)**	1.7 (0.9–3.3)	3.88 (0.91–16.4)**	1.59 (1.08–2.35)**
	TG/HDL-C ratio	2.3 (1.8–3.0)**	1.9 (1.3–2.8)**	3.1 (2.1–4.5)**	2.11 (1.31–3.39)**	2.56 (2.00–3.28)**
	Non-HDL-C (mg/dL)	1.04 (1.03–1.05)**	1.03 (1.02–1.05)**	1.04 (1.03–1.06)**	1.03 (1.02–1.05)**	1.05 (1.03–1.06)**
	ALT (IU/L)	1.03 (1.02–1.05)**	1.03 (1.02–1.04)**	1.05 (1.03–1.07)**	1.03 (1.02–1.04)**	1.06 (1.03–1.10)**
	WHtR (%)	1.4 (1.3–1.5)**	1.4 (1.3–1.5)**	1.4 (1.3–1.5)**	1.37 (1.28–1.46)**	1.48 (1.35–1.62)**
	BMI z-score	11.4 (7.3–17.8)**	13.5 (6.7–27.2)**	10.5 (5.6–19.7)**	15.4 (7.1–33.3)**	8.9 (5.1–15.6)**
CMRF clustering	HbA1c (%)	2.1 (1.1–4.0)**	2.0 (0.9–4.7)	2.0 (0.8–5.2)	3.7 (1.7, 7.9)**	1.7 (1.0–3.0)*
	TG/HDL-C ratio	3.9 (3.3–4.6)**	4.2 (3.4–5.3)**	4.1 (3.1–5.3)**	3.7 (3.0–4.5)**	4.6 (3.4–6.1)**
	Non-HDL-C (mg/dL)	1.03 (1.03–1.04)**	1.04 (1.03–1.04)**	1.03 (1.02–1.04)**	1.03 (1.02–1.04)**	1.03 (1.02–1.04)**
	ALT (IU/L)	1.05 (1.03–1.06)**	1.05 (1.02–1.07)**	1.05 (1.04–1.06)**	1.04 (1.03–1.05)**	1.06 (1.02–1.11)**
	WHtR (%)	1.3 (1.3–1.4)**	1.3 (1.2–1.4)**	1.3 (1.2–1.4)**	1.3 (1.2–1.4)**	1.3 (1.3–1.4)**
	BMI z-score	4.1 (3.2–5.2)**	4.7 (3.4–6.5)**	3.6 (2.6–5.1)**	4.6 (3.1–6.9)**	3.6 (2.6–4.9)**

\* $P < 0.05$ ,

\*\* $P < 0.01$

HbA1c: glycated hemoglobin; TG/HDL-C: triglyceride to high density lipoprotein cholesterol; ALT: alanine transaminase; WHtR: Waist circumference to height ratio; BMI: Body mass index.

<https://doi.org/10.1371/journal.pone.0186050.t002>

**Table 3. Area under the curve (95% confidence intervals) and cut-off values of surrogate markers for predicting metabolic syndrome and cardiometabolic risk factor (CMRF) clustering.**

Category	Surrogate markers	Total	10–15 years	16–19 years	Boys	Girls	Cut-off value	Sensitivity (%)	Specificity (%)
Metabolic syndrome (IDF)	HbA1c (%)	0.627 (0.625, 0.629)	0.637 (0.635, 0.639)	0.624 (0.621, 0.627)	0.621 (0.618, 0.623)	0.633 (0.630, 0.636)	5.5	70.5	50.5
	TG/HDL-C ratio	0.947 (0.946, 0.948)	0.965 (0.964, 0.965)	0.936 (0.934, 0.937)	0.934 (0.932, 0.935)	0.963 (0.962, 0.964)	2.64	95.1	86.4
	Non-HDL-C (mg/dL)	0.779 (0.778, 0.781)	0.747 (0.745, 0.749)	0.808 (0.806, 0.810)	0.735 (0.733, 0.737)	0.844 (0.842, 0.845)	111.6	81.3	63.7
	ALT (IU/L)	0.820 (0.819, 0.822)	0.816 (0.814, 0.818)	0.822 (0.820, 0.823)	0.867 (0.865, 0.868)	0.811 (0.809, 0.813)	21	63.5	88.2
	WHtR	0.960 (0.959, 0.960)	0.954 (0.953, 0.954)	0.964 (0.963, 0.964)	0.967 (0.967, 0.968)	0.957 (0.957, 0.957)	0.491	96.5	88.2
	BMI z-score	0.959 (0.957, 0.962)	0.957 (0.956, 0.957)	0.962 (0.961, 0.962)	0.966 (0.966, 0.966)	0.955 (0.954, 0.955)	1.35	95.1	89.4
CMRF clustering	HbA1c (%)	0.607 (0.606, 0.608)	0.596 (0.594, 0.597)	0.628 (0.627, 0.629)	0.580 (0.578, 0.581)	0.636 (0.634, 0.637)	5.6	50.0	66.8
	TG/HDL-C ratio	0.891 (0.891, 0.892)	0.917 (0.916, 0.918)	0.869 (0.868, 0.869)	0.898 (0.898, 0.899)	0.885 (0.884, 0.885)	2.63	74.4	90.5
	Non-HDL-C (mg/dL)	0.720 (0.719, 0.721)	0.716 (0.715, 0.717)	0.725 (0.724, 0.726)	0.708 (0.707, 0.709)	0.738 (0.737, 0.739)	118.7	60.1	75.2
	ALT (IU/L)	0.730 (0.729, 0.730)	0.780 (0.779, 0.781)	0.686 (0.685, 0.687)	0.798 (0.797, 0.799)	0.704 (0.702, 0.705)	15	61.8	74.4
	WHtR	0.842 (0.841, 0.843)	0.843 (0.842, 0.844)	0.840 (0.839, 0.841)	0.857 (0.856, 0.858)	0.829 (0.828, 0.830)	0.469	74.1	82.9
	BMI z-score	0.829 (0.828, 0.830)	0.839 (0.838, 0.840)	0.821 (0.820, 0.822)	0.853 (0.852, 0.854)	0.804 (0.803, 0.805)	1.06	68.2	87.2

All *P* values were <0.001 when compared AUC between age groups and sex.

HbA1c: glycated hemoglobin; TG/HDL-C: triglyceride to high density lipoprotein cholesterol; ALT: alanine transaminase; WHtR: waist circumference to height ratio; BMI: body mass index.

<https://doi.org/10.1371/journal.pone.0186050.t003>

the highest predictability for MetS, whereas TG/HDL-C ratio [0.891 (95% CI 0.891–0.892)] showed the highest predictability for CMRF clustering (Table 3). The cut-off values of WHtR were 0.491 (sensitivity 96.5% and specificity 88.5%) for MetS and 0.469 (sensitivity 74.1% and specificity 82.9%) for CMRF clustering (Table 3). BMI z-score showed the cut-off values of 1.35 (sensitivity 96.5% and specificity 88.5%) for MetS and 1.06 (sensitivity 68.2% and specificity 82.9%) for CMRF clustering. The cut-off points of TG/HDL-C ratio for predicting MetS and CMRF clustering were 2.64 (sensitivity 95.1% and specificity 86.4%) and 2.63 (sensitivity 74.4% and specificity 90.5%), respectively.

## Discussion

In the present study using the 2011–2014 KNHANES, the prevalence of MetS and CMRF clustering in children and adolescents aged 10–19 years was 1.8% and 8.9%, respectively. The degree of risk was higher as the WHtR and TG/HDL-C ratio increased.

Overall, the prevalence of MetS among our participants (1.8%) was similar to previous studies based on the IDF criteria in 2007–2008 KNHANES (1.9%) and 2005 KNHANES (1.8%) [8, 9]. Compared to the prevalence of 1.5% shown in the 2007–2009 KNHANES study conducted in 2716 individuals aged 10–20 years [10], the prevalence of MetS seems to be increasing, but an accurate comparison cannot be made because the participants in these two studies belong to different age groups. On the other hand, prevalence of MetS in the present study was lower



compared to the other studies of KNHANES conducted using the modified National Cholesterol Education Program (NCEP) in 1998, 2001, 2005, 2008, 2010–2014, where the prevalence was 7.5%, 9.8%, 10.9%, 6.7%, 6.2%, respectively [17, 18]. IDF guidelines state the criteria for hypertriglyceridemia as  $\geq 150$  mg/dL, which is higher than what the NCEP guidelines state ( $\geq 110$  mg/dL). Furthermore, the criteria for low HDL-C is  $< 40$  mg/dL for both genders, except in girls 16 and older (HDL-C  $< 50$  mg/dL) in NCEP guidelines, which is stricter. Hence, using IDF guidelines criteria with higher cut-off point results in lower prevalence of hypertriglyceridemia [7].

When compared to the existing data from previous studies, where the IDF guidelines for MetS in children and adolescents [10, 19], we noted that the proportion of abdominal obesity increased in girls while hypertriglyceridemia decreased, and low HDL-C decreased in both genders (abdominal obesity: 7.7% in 1998–2008 KNHANES, 9.9% in 2007–2009 KNHANES, and 10.2% in the present study; hypertriglyceridemia: 9.7%, 9.2%, and 7.9%; low HDL-C 21.6%, 17.9%, and 17.7% in boys and 26%, 21.8%, and 18.5% in girls, respectively). In a study evaluating the changes in metabolic syndrome in American and Korean Youth from 1997 to 2008 [20], the WC in Korean youth has shown a tendency to increase. On the other hand, according to NCEP, MetS has been increasing because of the increased prevalence of low HDL-C, hypertriglyceridemia, and abdominal obesity, although it is evaluated based on different guidelines [20]. In any case, after 2008, the rates of low HDL-C and hypertriglyceridemia in Korean youth seem to be decreasing.

Meanwhile, it should be noted that the rate of hyperglycemia dramatically decreased in both genders when results from this study are compared to the study that used 1998–2008 KNHANES data (18.3% vs. 8.1% in boys; 15.2% vs 5.1% in girls) [19]. In addition, the rate of CMRF clustering decreased in both genders (10.9% vs. 9.3% in boys; 9.6% vs. 8.1% in girls) which seems to be the result of decreases in the rate of hypertriglyceridemia, low HDL-C and hyperglycemia. Although the rate of central obesity in the Republic of Korea and China is lower than that of the United States of America, the rates of low HDL-C and hypertriglyceridemia are similar [10, 21, 22]. The present study showed a similar pattern to previous study performed in U.S. children and adolescents (low HDL-C, 18.1% for Koreans vs. 22.6% for Americans; hypertriglyceridemia, 8.6% vs. 8.9%; central obesity, 9.1% vs. 28.6%).

The most well-known risk factor for MetS and CVD is obesity [21–23] and there are more studies being conducted in an effort to find more diverse surrogate markers, such as hypertriglyceridemia, hyperglycemia and high BMI [24, 25]. Analysis of MetS and surrogate markers in this study showed that as BMI z-score increased, the degree of risk became higher [OR 11.4 (95% CI 7.3–17.8,  $P < 0.001$ )]. Cut-off values for BMI z-score predicting CMRF and MetS were 1.06 and 1.36, which corresponds 85<sup>th</sup> percentile and 91<sup>st</sup> percentile, respectively. This finding supports the recently published guidelines for pediatric obesity, that recommends performing screening test for comorbidities in children and adolescents with a BMI of  $\geq 85^{\text{th}}$  percentile [26]. The value of OR was especially higher in boys as compared with girls (Table 2). Data for adults in KNHANES also shows a higher OR value in males [27]. Additionally, boys had higher attributable risk rates of metabolic co-morbidities as compared with girls [8]. In the analysis of CMRF clustering surrogate markers (Table 3), the degree of risk for HbA1c and BMI were high, and the OR value of HbA1c was higher in girls.

In the present study, the elevated ALT value was included in CMRF clustering. It was found that elevated ALT level was weak surrogate marker for MetS and CMRF clustering. However, excess adiposity can result in hepatic insulin resistance, hepatic steatosis, and Nonalcoholic fatty liver disease (NAFLD), well-known components of MetS [28, 29]. Some studies showed that low ALT level is associated with ideal cardiovascular health behavior [30] and MetS has been shown to have a dose-response relationship with ALT level [31]. However, these studies

were mainly conducted on adults, so the basis for using ALT level as a surrogate marker for MetS in children seems insufficient.

AUC was the largest with the application of BMI z-score for MetS and WHtR for CMRF clustering among anthropometric factors. TG/HDL-C ratio showed the largest AUC for predicting MetS and CMRF clustering among laboratory surrogate markers (Table 3). Although there are some differences based on countries and races, cut-off point of 0.5 for WHtR is proposed as the universal cut-off for central obesity in both adults and children [32]. In a research paper that used 1998–2008 KNHANES data to analyze WHtR as an index of cardiometabolic risk, the optimal cut-off values for obesity screening was 0.51 in boys and 0.49 in girls, and in adolescents with central obesity, the rate of MetS was more than two times higher in those with WHtR  $\geq 0.5$ , and concluded that the validity of WHtR to identify CMRFs was higher than that of BMI [19]. However, the study did not suggest any cut-off values for predicting MetS or CMRF clustering. In the present study, the cut-off value of WHtR was 0.491 (sensitivity 96.5% specificity 88.2%) for MetS and 0.469 (sensitivity 74.1% specificity 82.9%) for CMRF clustering. In studies using the 2010–2014 KNHANES data [18] on children where NCEP ATP III criteria were applied, the optimal cut-off WHtR value for predicting MetS risk was 0.44 in boys and 0.43 in girls. These values are lower than that of the present study and are also different than 0.52 value that was proposed by an American study [33]. In a study where the IDF guidelines were applied, the cut-off values were low (0.465 for boys, and 0.455 for girls); however, this seemed to be due to differences in race [34].

In the present study, the AUC of WHtR was higher, with a slight difference, than that of BMI in both MetS and CMRF clustering, with a value close to 1. As an anthropometric predictor of MetS, there were many studies showing that WHtR was similar or superior to BMI or WC [35–38]. However, some suggest that these be used as prescreening tools for predicting cardiometabolic risks, because anthropometric variables have low sensitivity [39]. We propose that in light of the inconvenience of using the percentile chart as a reference for BMI or WC of children and adolescents, WHtR might be an appropriate screening tool that can be used in clinical practice.

In contrast to children and adolescents, there were many studies that analyzed the validity or cut-offs of HbA1c or fasting glucose as predictive factors for diabetes, MetS, and cardiovascular diseases in adults [40–42]. In the present study, we found that HbA1c had less predictive value for predicting MetS and CMRF clustering than other markers. This may be because children and adolescents had a narrower range of HbA1c levels than adults.

In the ROC analysis of present study, the AUC of TG/HDL-C ratio was the highest among the laboratory markers. In a research on CVD risk analysis on adults, elevated TG/HDL-C ratio was a marker that reflected insulin resistance and glycemic control and that it was effective in MetS diagnosis to predict the development of CVD. In those studies, the value for high risk group of MetS was ranged to be  $\geq 3.0$ – $3.5$  in males and  $\geq 2.0$  in females [43–46]. In a few studies done on the value of TG/HDL-C ratio in children, the mean TG/HDL-C ratio was 1.6–1.7 and 4.0 in the case of MetS, where the 95<sup>th</sup> percentile values were 3.83–4.61 [47, 48]. The cut-off of 2.64 in MetS and 2.63 in CMRF clustering in the present study belonged to approximately 75–90<sup>th</sup> percentile of Korean adolescents [48]. There are studies in which low cut-off values for MetS were TG/HDL-C ratio  $> 1.25$  and this was proposed as a better index than homeostatic model assessment for insulin resistance (HOMA-IR) index [49]. However, there are not enough studies on children and adolescents on this suggesting that further studies are needed to develop a consensus.

There are several limitations to this study. First, this study is cross-sectional, making it difficult to explain causal relationships or describe clear mechanisms related to surrogate markers of MetS and CMRF clustering. Secondly, because the HOMA-IR, which is known to reflect



insulin resistance best, was not obtained in this data, there was no comparison with HOMA-IR. Thirdly, this study only analyzed anthropometric and laboratory data, so the degree of risk for MetS depending on the difference in lifestyle could not be determined.

Despite these limitations, this study has several strengths. First, it is a nationwide epidemiologic study that found the prevalence of MetS and CMRF clustering and their predictors in children and adolescents. Secondly, to the best of our knowledge, this is the first study to suggest a cut-off value of WHtR and TG/HDL-C associated with the prevalence of MetS and CMRF clustering in the Korean children and adolescents.

## Conclusions

In conclusion, the prevalence of MetS and CMRF clustering was 1.8% and 8.9% in Korean children and adolescents. Most reliable predictors for MetS and CMRF clustering were WHtR in anthropometric parameters and TG/HDL-C ratio in laboratory markers. When TG/HDL-C ratio and waist-height ratio are compared, WHtR is significantly better in predicting MetS whereas TG/HDL-C ratio is significantly better in predicting CMRF clustering. Long-term follow-up is needed for further validation.

## Author Contributions

**Conceptualization:** Jae Hyun Kim.

**Data curation:** Jae Hyun Kim.

**Formal analysis:** Jae Hyun Kim.

**Funding acquisition:** Ji-Young Seo.

**Investigation:** Jae Hyun Kim.

**Methodology:** Jae Hyun Kim.

**Project administration:** Ji-Young Seo, Jae Hyun Kim.

**Resources:** Jae Hyun Kim.

**Software:** Jae Hyun Kim.

**Supervision:** Jae Hyun Kim.

**Validation:** Jae Hyun Kim.

**Visualization:** Ji-Young Seo, Jae Hyun Kim.

**Writing – original draft:** Ji-Young Seo.

**Writing – review & editing:** Ji-Young Seo, Jae Hyun Kim.

## References

1. Kaur J. A comprehensive review on metabolic syndrome. *Cardiol Res Pract.* 2014; 2014: 943162. <https://doi.org/10.1155/2014/943162> PMID: 24711954
2. Weiss R, Dziura J, Burgert TS, Tamborlane WV, Taksali SE, Yockel CW, et al. Obesity and the metabolic syndrome in children and adolescents. *N Engl J Med.* 2004; 350: 2362–74. <https://doi.org/10.1056/NEJMoa031049> PMID: 15175438
3. Laurson KR, Welk GJ, Eisenmann JC. Diagnostic performance of BMI percentiles to identify adolescents with metabolic syndrome. *Pediatrics.* 2014; 133: e330–8. <https://doi.org/10.1542/peds.2013-1308> PMID: 24470650

4. Camhi SM, Katzmarzyk PT. Tracking of cardiometabolic risk factor clustering from childhood to adulthood. *Int J Pediatr Obes*. 2010; 5: 122–9. Epub 2009/07/14. <https://doi.org/10.3109/17477160903111763> PMID: 19593726
5. Magge SN, Goodman E, Armstrong SC. The Metabolic Syndrome in Children and Adolescents: Shifting the Focus to Cardiometabolic Risk Factor Clustering. *Pediatrics*. 2017; Epub 2017/07/26. <https://doi.org/10.1542/peds.2017-1603> PMID: 28739653
6. Druet C, Ong K, Levy Marchal C. Metabolic syndrome in children: comparison of the International Diabetes Federation 2007 consensus with an adapted National Cholesterol Education Program definition in 300 overweight and obese French children. *Horm Res Paediatr*. 2010; 73: 181–6. <https://doi.org/10.1159/000284359> PMID: 20197670
7. Kim JW, Park SH, Kim Y, Im M, Han HS. The cutoff values of indirect indices for measuring insulin resistance for metabolic syndrome in Korean children and adolescents. *Ann Pediatr Endocrinol Metab*. 2016; 21: 143–8. Epub 2016/10/26. <https://doi.org/10.6065/apem.2016.21.3.143> PMID: 27777906
8. Lim H, Xue H, Wang Y. Association between obesity and metabolic co-morbidities among children and adolescents in South Korea based on national data. *BMC Public Health*. 2014; 14: 279. Epub 2014/03/29. <https://doi.org/10.1186/1471-2458-14-279> PMID: 24666605
9. Park MJ, Boston BA, Oh M, Jee SH. Prevalence and trends of metabolic syndrome among Korean adolescents: from the Korean NHANES survey, 1998–2005. *J Pediatr*. 2009; 155: 529–34. Epub 2009/06/27. <https://doi.org/10.1016/j.jpeds.2009.03.063> PMID: 19555969
10. Yi KH, Hwang JS, Kim EY, Lee SH, Kim DH, Lim JS. Prevalence of insulin resistance and cardiometabolic risk in Korean children and adolescents: a population-based study. *Diabetes Res Clin Pract*. 2014; 103: 106–13. Epub 2013/12/03. <https://doi.org/10.1016/j.diabres.2013.10.021> PMID: 24290751
11. Kweon S, Kim Y, Jang MJ, Kim Y, Kim K, Choi S, et al. Data resource profile: the Korea National Health and Nutrition Examination Survey (KNHANES). *Int J Epidemiol*. 2014; 43: 69–77. Epub 2014/03/04. <https://doi.org/10.1093/ije/dyt228> PMID: 24585853
12. Moon JS, Lee SY, Nam CM, Choi JM, Choe BK, Seo JW, et al. 2007 Korean National Growth Charts: review of developmental process and an outlook. *Korean J Pediatr*. 2008; 51: 1–25. <https://doi.org/10.3345/kjp.2008.51.1.1>
13. Zimmet P, Alberti KG, Kaufman F, Tajima N, Sillink M, Arslanian S, et al. The metabolic syndrome in children and adolescents—an IDF consensus report. *Pediatr Diabetes*. 2007; 8: 299–306. Epub 2007/09/14. <https://doi.org/10.1111/j.1399-5448.2007.00271.x> PMID: 17850473
14. Lee SY, Park HS, Kim DJ, Han JH, Kim SM, Cho GJ, et al. Appropriate waist circumference cutoff points for central obesity in Korean adults. *Diabetes Res Clin Pract*. 2007; 75: 72–80. Epub 2006/06/01. <https://doi.org/10.1016/j.diabres.2006.04.013> PMID: 16735075
15. Park HK, Hwang JS, Moon JS, Lee JA, Kim DH, Lim JS. Healthy range of serum alanine aminotransferase and its predictive power for cardiovascular risk in children and adolescents. *J Pediatr Gastroenterol Nutr*. 2013; 56: 686–91. Epub 2013/02/14. <https://doi.org/10.1097/MPG.0b013e31828b4e67> PMID: 23403445
16. Akobeng AK. Understanding diagnostic tests 3: Receiver operating characteristic curves. *Acta Paediatr*. 2007; 96: 644–7. Epub 2007/03/23. <https://doi.org/10.1111/j.1651-2227.2006.00178.x> PMID: 17376185
17. Chung JY, Kang HT, Shin YH, Lee HR, Park BJ, Lee YJ. Prevalence of metabolic syndrome in children and adolescents—the recent trends in South Korea. *J Pediatr Endocrinol Metab*. 2013; 26: 105–10. Epub 2013/01/19. <https://doi.org/10.1515/jpem-2012-0294> PMID: 23329742
18. Choi DH, Hur YI, Kang JH, Kim K, Cho YG, Hong SM, Cho EB. Usefulness of the Waist Circumference-to-Height Ratio in Screening for Obesity and Metabolic Syndrome among Korean Children and Adolescents: Korea National Health and Nutrition Examination Survey, 2010–2014. *Nutrients*. 2017; 9: E256. <https://doi.org/10.3390/nu9030256> PMID: 28287410.
19. Chung IH, Park S, Park MJ, Yoo EG. Waist-to-Height Ratio as an Index for Cardiometabolic Risk in Adolescents: Results from the 1998–2008 KNHANES. *Yonsei Med J*. 2016; 57: 658–63. Epub 2016/03/22. <https://doi.org/10.3349/ymj.2016.57.3.658> PMID: 26996566
20. Lim S, Jang HC, Park KS, Cho SI, Lee MG, Joung H, et al. Changes in metabolic syndrome in American and Korean youth, 1997–2008. *Pediatrics*. 2013; 131: e214–22. Epub 2012/12/05. <https://doi.org/10.1542/peds.2012-0761> PMID: 23209102
21. Ford ES, Li C, Zhao G, Pearson WS, Mokdad AH. Prevalence of the metabolic syndrome among U.S. adolescents using the definition from the International Diabetes Federation. *Diabetes Care*. 2008; 31: 587–9. Epub 2007/12/12. <https://doi.org/10.2337/dc07-1030> PMID: 18071007
22. Chen F, Wang Y, Shan X, Cheng H, Hou D, Zhao X, et al. Association between childhood obesity and metabolic syndrome: evidence from a large sample of Chinese children and adolescents. *PLoS One*. 2012; 7: e47380. Epub 2012/10/20. <https://doi.org/10.1371/journal.pone.0047380> PMID: 23082159

23. Chen W, Srinivasan SR, Li S, Xu J, Berenson GS. Clustering of long-term trends in metabolic syndrome variables from childhood to adulthood in Blacks and Whites: the Bogalusa Heart Study. *Am J Epidemiol*. 2007; 166: 527–33. Epub 2007/06/19. <https://doi.org/10.1093/aje/kwm105> PMID: 17573336
24. Casavalle PL, Lifshitz F, Romano LS, Pandolfo M, Caamano A, Boyer PM, et al. Prevalence of dyslipidemia and metabolic syndrome risk factor in overweight and obese children. *Pediatr Endocrinol Rev*. 2014; 12: 213–23. Epub 2015/01/15. PMID: 25581987
25. Lo K, Wong M, Khalechelvam P, Tam W. Waist-to-height ratio, body mass index and waist circumference for screening paediatric cardio-metabolic risk factors: a meta-analysis. *Obes Rev*. 2016; 17: 1258–75. Epub 2016/07/28. <https://doi.org/10.1111/obr.12456> PMID: 27452904
26. Styne DM, Arslanian SA, Connor EL, Farooqi IS, Murad MH, Silverstein JH, et al. Pediatric Obesity—Assessment, Treatment, and Prevention: An Endocrine Society Clinical Practice Guideline. *J Clin Endocrinol Metab*. 2017; 102: 709–57. Epub 2017/03/31. <https://doi.org/10.1210/jc.2016-2573> PMID: 28359099
27. Yoon SH, Han KT, Kim SJ, Sohn TY, Jeon B, Kim W, et al. Combined effect of body mass index and body size perception on metabolic syndrome in South Korea: results of the fifth Korea National Health and Nutrition Examination Surveys (2010–2012). *BMC Public Health*. 2015; 15: 554. Epub 2015/06/18. <https://doi.org/10.1186/s12889-015-1839-6> PMID: 26081846
28. Labayen I, Ruiz JR, Ortega FB, Davis CL, Rodriguez G, Gonzalez-Gross M, et al. Liver enzymes and clustering cardiometabolic risk factors in European adolescents: the HELENA study. *Pediatr Obes*. 2015; 10: 361–70. Epub 2014/12/18. <https://doi.org/10.1111/ijpo.273> PMID: 25515703
29. Kotronen A, Seppala-Lindroos A, Bergholm R, Yki-Jarvinen H. Tissue specificity of insulin resistance in humans: fat in the liver rather than muscle is associated with features of the metabolic syndrome. *Diabetologia*. 2008; 51: 130–8. Epub 2007/11/17. <https://doi.org/10.1007/s00125-007-0867-x> PMID: 18008059
30. Labayen I, Ruiz JR, Huybrechts I, Ortega FB, Castillo M, Sjostrom M, et al. Ideal cardiovascular health and liver enzyme levels in European adolescents; the HELENA study. *J Physiol Biochem*. 2017; Epub 2017/01/08. <https://doi.org/10.1007/s13105-016-0546-9> PMID: 28063097
31. Wu P, Chen Q, Chen L, Zhang P, Xiao J, Chen X, et al. Dose-Response Relationship between Alanine Aminotransferase Levels within the Reference Interval and Metabolic Syndrome in Chinese Adults. *Yonsei Med J*. 2017; 58: 158–64. Epub 2016/11/23. <https://doi.org/10.3349/ymj.2017.58.1.158> PMID: 27873509
32. Yoo EG. Waist-to-height ratio as a screening tool for obesity and cardiometabolic risk. *Korean J Pediatr*. 2016; 59: 425–31. Epub 2016/11/30. <https://doi.org/10.3345/kjp.2016.59.11.425> PMID: 27895689
33. Bauer KW, Marcus MD, El ghormli L, Ogden CL, Foster GD. Cardio-metabolic risk screening among adolescents: understanding the utility of body mass index, waist circumference and waist to height ratio. *Pediatr Obes*. 2015; 10: 329–37. Epub 2014/12/18. <https://doi.org/10.1111/ijpo.267> PMID: 25515620
34. Matsha TE, Kengne AP, Yako YY, Hon GM, Hassan MS, Erasmus RT. Optimal waist-to-height ratio values for cardiometabolic risk screening in an ethnically diverse sample of South African urban and rural school boys and girls. *PLoS One*. 2013; 8: e71133. Epub 2013/08/24. <https://doi.org/10.1371/journal.pone.0071133> PMID: 23967160
35. Hara M, Saitou E, Iwata F, Okada T, Harada K. Waist-to-height ratio is the best predictor of cardiovascular disease risk factors in Japanese schoolchildren. *J Atheroscler Thromb*. 2002; 9: 127–32. Epub 2002/09/13. PMID: 12226553
36. Savva SC, Tornaritis M, Savva ME, Kourides Y, Panagi A, Silikiotou N, et al. Waist circumference and waist-to-height ratio are better predictors of cardiovascular disease risk factors in children than body mass index. *Int J Obes Relat Metab Disord*. 2000; 24: 1453–8. Epub 2000/01/11. PMID: 11126342
37. Kahn HS, Imperatore G, Cheng YJ. A population-based comparison of BMI percentiles and waist-to-height ratio for identifying cardiovascular risk in youth. *J Pediatr*. 2005; 146: 482–8. Epub 2005/04/07. <https://doi.org/10.1016/j.jpeds.2004.12.028> PMID: 15812450
38. Manios Y, Kourlaba G, Kafatos A, Cook TL, Spyridaki A, Fragiadakis GA. Associations of several anthropometric indices with insulin resistance in children: The Children Study. *Acta Paediatr*. 2008; 97: 494–9. Epub 2008/03/28. <https://doi.org/10.1111/j.1651-2227.2008.00729.x> PMID: 18363958
39. Sardinha LB, Santos DA, Silva AM, Grontved A, Andersen LB, Ekelund U. A Comparison between BMI, Waist Circumference, and Waist-To-Height Ratio for Identifying Cardio-Metabolic Risk in Children and Adolescents. *PLoS One*. 2016; 11: e0149351. Epub 2016/02/24. <https://doi.org/10.1371/journal.pone.0149351> PMID: 26901828
40. Selvin E, Steffes MW, Zhu H, Matsushita K, Wagenknecht L, Pankow J, et al. Glycated hemoglobin, diabetes, and cardiovascular risk in nondiabetic adults. *N Engl J Med*. 2010; 362: 800–11. Epub 2010/03/05. <https://doi.org/10.1056/NEJMoa0908359> PMID: 20200384

41. Khaw KT, Wareham N, Bingham S, Luben R, Welch A, Day N. Association of hemoglobin A1c with cardiovascular disease and mortality in adults: the European prospective investigation into cancer in Norfolk. *Ann Intern Med.* 2004; 141: 413–20. Epub 2004/09/24. PMID: [15381514](#)
42. Meigs JB, Nathan DM, D'Agostino RB Sr., Wilson PW. Fasting and postchallenge glycemia and cardiovascular disease risk: the Framingham Offspring Study. *Diabetes Care.* 2002; 25: 1845–50. Epub 2002/09/28. PMID: [12351489](#)
43. Salazar MR, Carbajal HA, Espeche WG, Aizpurua M, Leiva Sisniegues CE, March CE, et al. Identifying cardiovascular disease risk and outcome: use of the plasma triglyceride/high-density lipoprotein cholesterol concentration ratio versus metabolic syndrome criteria. *J Intern Med.* 2013; 273: 595–601. Epub 2013/01/22. <https://doi.org/10.1111/joim.12036> PMID: [23331522](#)
44. Armato J, Reaven G, Ruby R. TRIGLYCERIDE/HIGH-DENSITY LIPOPROTEIN CHOLESTEROL CONCENTRATION RATIO IDENTIFIES ACCENTUATED CARDIOMETABOLIC RISK. *Endocr Pract.* 2015; 21: 495–500. Epub 2015/02/11. <https://doi.org/10.4158/EP14479.OR> PMID: [25667373](#)
45. Quispe R, Martin SS, Jones SR. Triglycerides to high-density lipoprotein-cholesterol ratio, glycemic control and cardiovascular risk in obese patients with type 2 diabetes. *Curr Opin Endocrinol Diabetes Obes.* 2016; 23: 150–6. Epub 2016/02/11. <https://doi.org/10.1097/MED.0000000000000241> PMID: [26863278](#)
46. Sung KC, Reaven G, Kim S. Ability of the plasma concentration ratio of triglyceride/high-density lipoprotein cholesterol to identify increased cardio-metabolic risk in an east Asian population. *Diabetes Res Clin Pract.* 2014; 105: 96–101. Epub 2014/05/21. <https://doi.org/10.1016/j.diabres.2014.04.021> PMID: [24842244](#)
47. Quijada Z, Paoli M, Zerpa Y, Camacho N, Cichetti R, Villarroel V, et al. The triglyceride/HDL-cholesterol ratio as a marker of cardiovascular risk in obese children; association with traditional and emergent risk factors. *Pediatr Diabetes.* 2008; 9: 464–71. Epub 2008/05/30. <https://doi.org/10.1111/j.1399-5448.2008.00406.x> PMID: [18507788](#)
48. Shim YS, Baek JW, Kang MJ, Oh YJ, Yang S, Hwang IT. Reference Values for The Triglyceride to High-Density Lipoprotein Cholesterol Ratio and Non-High-Density Lipoprotein Cholesterol in Korean Children and Adolescents: The Korean National Health and Nutrition Examination Surveys 2007–2013. *J Atheroscler Thromb.* 2016; 23: 1334–44. Epub 2016/07/05. PMID: [27373984](#)
49. Liang J, Fu J, Jiang Y, Dong G, Wang X, Wu W. TriGlycerides and high-density lipoprotein cholesterol ratio compared with homeostasis model assessment insulin resistance indexes in screening for metabolic syndrome in the chinese obese children: a cross section study. *BMC Pediatr.* 2015; 15: 138. Epub 2015/09/30. <https://doi.org/10.1186/s12887-015-0456-y> PMID: [26416207](#)